SHS Capital Revenue and Competitors
Employee Data
- SHS Capital has 52 Employees.
- SHS Capital grew their employee count by 27% last year.
SHS Capital's People
Name | Title | Email/Phone |
---|
SHS Capital Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | N/A | 52 | 41% | N/A | N/A |
#2 | N/A | 28 | 17% | N/A | N/A |
#3 | N/A | 55 | 38% | N/A | N/A |
#4 | N/A | 52 | 27% | N/A | N/A |
#5 | N/A | 28 | 40% | N/A | N/A |
#6 | N/A | 22 | 22% | N/A | N/A |
#7 | N/A | 74 | 21% | N/A | N/A |
#8 | N/A | 5 | 67% | N/A | N/A |
#9 | N/A | 164 | 5% | N/A | N/A |
#10 | N/A | 3 | 200% | N/A | N/A |
What Is SHS Capital?
At SHS Capital we are committed to Building European Healthcare Champions, by helping to accelerate our portfolio companies' growth. We do that by following high ethical and sustainable standards. If you are looking for the right partner to bring your Healthcare company to the next level, reach out!\n\nhttps://www.shs-capital.eu/\n\nWe focus on\nPhases: Growth cases and “Mittelstand” companies\nRegions: DACH, Benelux, and the NordicsIndustries: Life science, Medical technology, Diagnostics, Digital health, Applied technologies, and industrial biotechnology & pharmaceuticals (no drug development)\n\nInvestors can participate in a diversified portfolio of innovative companies from the life science and medical technology sector via SHS funds. Our investor base comprises private and institutional investor groups with a long-term focus. We currently host investors from well-known family offices, pension funds, pension schemes, fund of funds, banks, churches, health insurance companies, industrial companies, the European Investment Fund, and the KfW.
keywords:N/AN/A
Total Funding
52
Number of Employees
N/A
Revenue (est)
27%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | N/A | 76 | 33% | N/A |
#2 | N/A | 99 | 29% | N/A |
#3 | N/A | 152 | 19% | N/A |
#4 | N/A | 156 | 21% | N/A |
#5 | $49M | 219 | 10% | N/A |